Alaunos Therapeutics Reports Q2 2026 Financial Results with $952,000 Net Loss

Alaunos Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $952,000, a slight decrease from the $1.051 million loss recorded in the same period of 2025. For the first half of 2026, the company reported a net loss of $1.958 million, compared to $2.124 million for the first half of 2025. The company has not generated any revenue from product sales, maintaining an accumulated deficit of approximately $926.6 million since its inception in 2003. As of June 30, 2026, Alaunos had cash and cash equivalents of $124,000, a significant decline from $1.385 million at the end of 2025.

Operating expenses for the second quarter of 2026 totaled $952,000, down from $1.039 million in the same quarter of the previous year. The decrease was primarily attributed to a reduction in general and administrative expenses, which fell to $564,000 from $854,000 year-over-year. Conversely, research and development expenses increased to $388,000 from $185,000, reflecting higher stock-based compensation and consulting fees associated with the company's focus on its obesity and metabolic disorders program. The company’s total liabilities stood at $864,000, up from $813,000 at the end of 2025.

In terms of strategic developments, Alaunos is advancing its preclinical small molecule program targeting obesity and related metabolic disorders. The company has identified a lead compound, ALN1003, which has shown promising results in preclinical studies involving diet-induced obesity mouse models. These studies indicated significant reductions in body weight and improvements in metabolic parameters, suggesting potential therapeutic benefits. The company plans to conduct further preclinical studies and has initiated small-scale manufacturing activities for ALN1003.

Alaunos has faced challenges regarding its listing on the Nasdaq Capital Market, receiving a notice in April 2026 indicating that its stockholders' equity did not meet the minimum requirement of $2.5 million. The company has submitted a plan to regain compliance and is actively working with Nasdaq. As of June 30, 2026, Alaunos had 2,486,140 shares of common stock outstanding, with no revenue generated from collaborations or product sales during the reporting period.

Looking ahead, Alaunos anticipates continued operating losses as it progresses its research and development efforts. The company has indicated that its current cash resources will not be sufficient to fund operations for at least one year, raising substantial doubt about its ability to continue as a going concern. To sustain its operations and advance its programs, Alaunos will need to secure additional financing, which may not be guaranteed. The company is exploring various strategic financing and collaboration opportunities to support its ongoing development initiatives.